Tel Aviv, Israel-based Sight Diagnostics, which operates an AI-powered blood testing company, announced it has raised $27.8 million in Series C funding led by Longliv Ventures, a member of the CK Hutchison Group. Other investors in the round include healthcare philanthropist Jack Nicklaus II; Steven Esrick, a healthcare impact investor; and an additional major medical equipment manufacturer. Also joining the company's Series C funding are existing investors OurCrowd, Go Capital and New Alliance Capital.